Photo from wikipedia
SUMMARY Developing effective therapies in anti-PD-1-resistant melanoma is a key unmet need. The combination of pembrolizumab with the intralesional TLR9 agonist vidutolimod showed promise in this patient population with correlative… Click to show full abstract
SUMMARY Developing effective therapies in anti-PD-1-resistant melanoma is a key unmet need. The combination of pembrolizumab with the intralesional TLR9 agonist vidutolimod showed promise in this patient population with correlative analysis suggesting that patients with a "cold" tumor immune microenvironment may be the best patients to study further. See related article by Ribas et al., p. 2998.
Keywords:
tolls toll;
resistant melanoma;
bell tolls;
anti resistant;
toll like
Journal Title: Cancer discovery
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer discovery
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!